Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.

Complement--tapping into new sites and effector systems. Nat Rev Immunol (2014) 1.30

Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. Mol Oral Microbiol (2015) 0.80

Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18. Thromb Haemost (2015) 0.78

ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. J Exp Med (1965) 15.47

Large scale isolation of functionally active components of the human complement system. J Biol Chem (1981) 5.26

Structures of complement component C3 provide insights into the function and evolution of immunity. Nature (2005) 4.01

Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med (1980) 2.94

Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med (1981) 2.88

The covalent-binding reaction of complement component C3. Biochem J (1981) 2.80

Membrane lipid composition and cellular function. J Lipid Res (1985) 2.71

Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem (1999) 2.33

Purification of C3b inactivator and demonstration of its two polypeptide chain structure. J Immunol (1977) 2.16

The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci (1997) 2.12

Human anaphylatoxin (C3a) from the third component of complement. Primary structure. J Biol Chem (1975) 2.08

Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin. J Exp Med (1983) 2.07

Autolytic fragmentation of complement components C3 and C4 under denaturing conditions, a property shared with alpha 2-macroglobulin. Biochem J (1981) 1.78

Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem (2006) 1.72

Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol (2008) 1.66

Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol (2013) 1.64

The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol (1991) 1.34

Quartz crystal microbalance with dissipation monitoring of supported lipid bilayers on various substrates. Nat Protoc (2010) 1.34

Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep (2002) 1.33

Liposome opsonization. J Liposome Res (2005) 1.26

Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials (2005) 1.25

Liposome clearance. Biosci Rep (2002) 1.25

Generation of iC3 at the interface between blood and gas. Scand J Immunol (1992) 1.24

Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J Biol Chem (2010) 1.20

Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res (1994) 1.17

Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3. Ann N Y Acad Sci (1983) 1.17

Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev (2011) 1.15

Isolation and biochemical characterization of the iC3b receptor of Candida albicans. Infect Immun (1993) 1.12

A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells. J Immunol (1997) 1.10

Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim Biophys Acta (1994) 1.10

Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes. J Immunol (1977) 1.09

Production of mouse monoclonal antibodies that detect distinct neoantigenic epitopes on bound C3b and iC3b but not on the corresponding soluble fragments. Mol Immunol (1987) 1.03

Hirudin versus heparin for use in whole blood in vitro biocompatibility models. J Biomed Mater Res A (2009) 1.01

Structural and functional analysis of C3 using monoclonal antibodies. Curr Top Microbiol Immunol (1990) 1.01

Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol (2010) 0.98

Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta (2001) 0.96

Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain. J Exp Med (1992) 0.93

Complement activation-related pseudoallergy caused by amphiphilic drug carriers: the role of lipoproteins. Curr Drug Deliv (2005) 0.92

Conformational epitopes of C3 reflecting its mode of binding to an artificial polymer surface. Mol Immunol (1993) 0.91

Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. Biochim Biophys Acta (2001) 0.89

Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction. Clin Exp Immunol (1993) 0.86

The role of immunoproteins in the survival of liposomes in the circulation. Crit Rev Ther Drug Carrier Syst (1997) 0.85

Effects of complement depletion on the pharmacokinetics and gene delivery mediated by cationic lipid-DNA complexes. Hum Gene Ther (1998) 0.84

The interaction of liposomes with the complement system: in vitro and in vivo assays. Methods Enzymol (2003) 0.83

Role of complements C3 and C5 in the phagocytosis of liposomes by human neutrophils. Pharm Res (1991) 0.82

Liposome clearance from blood: different animal species have different mechanisms. Biochim Biophys Acta (1995) 0.82

Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions. J Liposome Res (2009) 0.81

Liposome-mediated triggering of complement cascade. J Liposome Res (2008) 0.81

A simplified assay for the detection of C3a in human plasma employing a monoclonal antibody raised against denatured C3. J Immunol Methods (1988) 0.81

Complement-mediated acute effects of liposome-encapsulated hemoglobin. Artif Cells Blood Substit Immobil Biotechnol (1999) 0.79

Interactions between DMPC liposomes and the serum blood proteins HSA and IgG. J Phys Chem B (2009) 0.78

Biodistribution of liposomes and C3 fragments associated with liposomes: evaluation of their relationship. Int J Pharm (2000) 0.76